Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture

• Status: Terminated
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Prolongation of the analgesic effect of a femoral nerve block from the present 15 hours to 24 hours in patients with hip fracture would have a major impact in order to provide better preoperative analgesia for this group.

In other trials concerning other nerves then the femoral nerve the addition of Dexamethasone to the local anesthetics doubled the analgesic duration. No studies has investigated the effect of the addition of Dexamethasone to the femoral nerve block in patients with hip fracture.

The aim of our study is to investigate if more patients with hip fracture experience lasting preoperative analgesia until the time of operation or 20 hours after a femoral nerve block with the addition of Dexamethasone compared to the same nerve block done without Dexamethasone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: BB 1101; Bupivacaine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Clinical suspicion of hip fracture

• Age ≥ 55 years

• Mentally capable of comprehending and using verbal pain score

• Mentally capable of differentiating between pain from the fractured hip and pain from other locations

• Mentally capable of understanding the given information

• Arrival in the emergency room at times when one of the doctors who do the nerve blocks for this investigation are on call

• Verbal pain score (0-10) ≥ 7 with passive leg raise of the fractured leg at the time of inclusion

• Patients informed consent

Exclusion Criteria:

• Hip fracture not confirmed by x-ray

• Weight < 40 kg

• Verbal pain score > 3, 30 minutes after the nerve block

• Verbal pain score > 5 with passive leg raise, 30 minutes after the nerve block

• Patient has previously been included in this trial

• Ongoing pre traumatic treatment with parenteral or intravenous adrenocortical hormone

• Verbal pain score > 3 from other locations than the fractured hip

• If the patient wishes to be excluded

• Allergy to local anesthetics or adrenocortical hormone

• Visible infection in the area of the point of needle injection

• Acute inability to comprehend and use verbal pain score